

# Randomised Comparison of Cyclical Anthracycline-Based Chemotherapy [PA(BI)OE] with Alternating Chemotherapy [ChlVPP /PABIOE] in Advanced Hodgkin's Disease

<b>Submission date</b> 19/08/2002	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 19/08/2002	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 29/10/2019	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr - -

### Contact details

UKCCCR Register Co-ordinator  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

## Study information

### Scientific Title

Randomised Comparison of Cyclical Anthracycline-Based Chemotherapy [PA(BI)OE] with Alternating Chemotherapy [ChIVPP/PABIOE] in Advanced Hodgkin's Disease

### Study objectives

Not provided at time of registration

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Not specified

### Study type(s)

Not Specified

### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

### Health condition(s) or problem(s) studied

Lymphoma (Hodgkin's)

### Interventions

1. PA(BI)OE Regimen: Multi-drug chemotherapy with adriamycin, vincristine, prednisolone, etoposide and bleomycin [PA(BI)OE] cycle repeated every 21 days. A minimum of six courses to be given with at least two following documentation of clinical complete remission and a maximum of eight courses. Bleomycin to be given for the first four courses only.

2. ChIVPP/PABIOE Regimen: Multi-drug chemotherapy with chlorambucil, procarbazine, prednisolone and vinblastine (ChIVPP) alternating every 21 days with PABIOE.

### Intervention Type

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Cancer drug

**Primary outcome measure**

Not provided at time of registration

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/01/1990

**Completion date**

30/04/1996

## Eligibility

**Key inclusion criteria**

1. All previously untreated and properly staged patients aged between 15 and 69 years (inclusive) with Hodgkin's disease for whom chemotherapy is indicated are eligible for this trial, ie Stage I & IIA (poor prognosis), IB, IIB, III, IV
2. Patients must be free from any irreversible medical condition that would drastically limit their life span or prohibit the use of combination chemotherapy. This applies particularly to elderly patients
3. Adequate long term follow-up must be possible

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Not Specified

**Target number of participants**

Not provided at time of registration

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/01/1990

**Date of final enrolment**

30/04/1996

# Locations

## Countries of recruitment

England

United Kingdom

## Study participating centre

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

# Sponsor information

## Organisation

British National Lymphoma Investigation (BNLI) (UK)

## Sponsor details

CRC and UCL Cancer Trials Centre

222 Euston Road

London

United Kingdom

NW1 2DA

+44 (0)20 7679 8060

bnli@ctc.ucl.ac.uk

## Sponsor type

Charity

## Website

<http://www.bnli.ucl.ac.uk>

# Funder(s)

## Funder type

Research organisation

## Funder Name

British National Lymphoma Investigation, Central Lymphoma Group (UK)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration